KIDS

KIDS

USD

OrthoPediatrics Corp. Common Stock

$21.400+0.230 (1.086%)

实时价格

Healthcare
医疗设备
美国

价格图表

Loading Chart...

关键指标

市场指标
公司基本面
交易统计

市场指标

开盘价

$21.170

最高价

$21.680

最低价

$20.830

成交量

0.00M

公司基本面

市值

531.4M

所属行业

医疗设备

国家/地区

United States

交易统计

平均成交量

0.21M

交易所

NGM

货币

USD

52周价格范围

最低价 $20.247当前价 $21.400最高价 $35.99

AI分析报告

最后更新: 2025年5月4日
由AI生成数据来源: Yahoo Finance, Bloomberg, SEC

OrthoPediatrics Corp. (KIDS): What Recent News, Price Swings, and AI Predictions Tell Us

Stock Symbol: KIDS Generate Date: 2025-05-04 14:42:15

Let's break down what's been happening with OrthoPediatrics Corp., ticker symbol KIDS. This company focuses specifically on orthopedic stuff for kids – think implants, braces, and tools for young patients needing bone or spine help.

The Latest Buzz: What the News is Saying

Looking at the recent news, it's a bit of a mixed bag, but with some notable positives.

First off, we've got analysts weighing in. Needham and Lake Street both have "Buy" ratings on the stock, with price targets set quite a bit higher than where the stock is trading now – $42 and $37 respectively. Citizens Capital Markets is also bullish, calling it "Market Outperform" with an even higher $50 target. That's a lot of analysts seeing significant room for the stock to climb.

On the flip side, Truist Securities recently lowered their price target slightly, from $26 down to $24, while keeping a "Hold" rating. So, not everyone is quite as optimistic in the short term, though even their lower target is above the current price.

Beyond the analyst chatter, the company itself has put out some good news. They launched a new system called VerteGlide™ for scoliosis treatment, which is a big deal as it expands their product line in a key area. They also got recognized as one of the "Best Places to Work" in Indiana, which can be a good sign for company culture and stability.

So, the news vibe is generally positive, driven by new products and analyst confidence, even with one analyst being a bit more cautious.

Checking the Price Tag: What the Chart Shows

Now, let's look at what the stock price itself has been doing over the last month or so. The historical data shows that after some ups and downs in March, the price started a noticeable slide in April. It dropped from the mid-$20s down towards the low $20s.

Recently, though, the price seems to have found a floor, trading in a tighter range around the $21 mark. The last recorded price was $21.40 (as of May 2nd). This is pretty close to the stock's 52-week low of $20.247.

Comparing the current price to the trend, it looks like the stock has pulled back significantly but might be trying to stabilize after that April dip.

Putting It All Together: What Might Be Next?

Okay, let's connect the dots. We have a company with positive recent news (new product, award) and several analysts who think the stock is worth a lot more than it is now. At the same time, the stock price has been weak lately, dropping considerably in April, though it seems to be holding steady right around its recent lows.

What does this combination suggest? Well, the recent price drop might have created a situation where the stock is trading well below what many analysts believe it's worth. The AI prediction model seems to agree, forecasting a potential upward move from here – predicting small gains over the next couple of days (0% today, +2.48% tomorrow, +3.81% the day after). The AI's overall recommendation score also leans positive (68.8), highlighting factors like positive news sentiment, potential undervaluation based on P/E compared to the industry, and technical signs like price being near support and a surge in trading volume (though the volume surge mentioned in the AI data seems specific to a particular moment, not the general trend shown in the historical data table).

Given the mix of positive analyst views, recent good company news, the stock pulling back significantly, and the AI predicting an upward bounce from this lower level, the situation might suggest a potential 'accumulate' or 'hold' leaning for those interested in the stock.

Potential Entry Consideration: If someone were considering getting in, the current price area, hovering around $21-$22, looks like a potential spot. Why? Because it's near recent lows where the price seems to be stabilizing, and it aligns with the area where the AI predicts an upward move could start. The AI recommendation data specifically points to potential entry points around $21.47 and $21.66, which are right in this range.

Potential Exit/Stop-Loss Consideration: Managing risk is always key. Based on the AI recommendation data, a potential level to consider taking profits could be around $23.23. This is below the higher analyst targets but represents a decent bounce from the current level. For cutting losses if the price turns south again, the AI suggests a stop-loss at $19.28. This level is below the recent 52-week low, acting as a point to exit if the stock breaks down significantly.

A Little More Context

Remember, OrthoPediatrics is a medical device company focused on a specific niche – kids' orthopedics. This focus means their success is tied to advancements and adoption in that specialized field. It's also a relatively smaller company with a market cap around $531 million. Smaller companies can sometimes be more volatile. While they have strong revenue growth (40%), the company isn't currently profitable (negative P/E and ROE) and carries some debt, which are factors to keep in mind.


Disclaimer: This analysis is based solely on the provided data and is for informational purposes only. It is not financial advice. Stock investing involves risk, and prices can go down as well as up. You should always conduct your own thorough research and consider consulting with a qualified financial advisor before making any investment decisions.

相关新闻

Analyst Upgrades

Truist Securities Maintains Hold on OrthoPediatrics, Lowers Price Target to $24

Truist Securities analyst Richard Newitter maintains OrthoPediatrics with a Hold and lowers the price target from $26 to $24.

查看更多
Truist Securities Maintains Hold on OrthoPediatrics, Lowers Price Target to $24
Analyst Upgrades

Needham Reiterates Buy on OrthoPediatrics, Maintains $42 Price Target

Needham analyst Mike Matson reiterates OrthoPediatrics with a Buy and maintains $42 price target.

查看更多
Needham Reiterates Buy on OrthoPediatrics, Maintains $42 Price Target
GlobeNewswire

OrthoPediatrics Corp. Expands Scoliosis Portfolio with Launch of VerteGlide™ System

WARSAW, Ind., April 08, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced

查看更多
OrthoPediatrics Corp. Expands Scoliosis Portfolio with Launch of VerteGlide™ System
Analyst Upgrades

Lake Street Initiates Coverage On OrthoPediatrics with Buy Rating, Announces Price Target of $37

Lake Street analyst Ben Haynor initiates coverage on OrthoPediatrics with a Buy rating and announces Price Target of $37.

查看更多
Lake Street Initiates Coverage On OrthoPediatrics with Buy Rating, Announces Price Target of $37
GlobeNewswire

OrthoPediatrics Corp. to Participate in the 24th Annual Needham Virtual Healthcare Conference

WARSAW, Ind., March 25, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced

查看更多
OrthoPediatrics Corp. to Participate in the 24th Annual Needham Virtual Healthcare Conference
GlobeNewswire

OrthoPediatrics Corp. Named One the 2025 Best Places to Work in Indiana

WARSAW, Ind., March 24, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced

Analyst Upgrades

Citizens Capital Markets Reiterates Market Outperform on OrthoPediatrics, Maintains $50 Price Target

Citizens Capital Markets analyst David Turkaly reiterates OrthoPediatrics with a Market Outperform and maintains $50 price target.

AI预测Beta

AI建议

看涨

更新于: 2025年5月5日 04:54

看跌中性看涨

68.7% 置信度

风险与交易

风险等级3/5
中风险
适合于
价值增长
交易指南

入场点

$21.47

止盈点

$23.23

止损点

$19.28

关键因素

PDI 14.0高于MDI 13.5,且ADX 12.9,表明看涨趋势
当前价格非常接近支撑水平$21.42,表明有强烈的买入机会
交易量是平均值的8.2倍(2,147),表明极强的买入压力
MACD 0.0024低于信号线0.0179,表明看跌交叉

保持更新

设置价格提醒,获取AI分析更新和实时市场新闻。